September 21, 2018
HESI is honored to be recognized as a featured contributor to today’s inaugural Biden Cancer Summit in Washington, DC. HESI was selected amongst a pool of national applicants as a leader in developing new innovative programs and partnerships that will double the rate of progress against cancer and improve the cancer patient experience. HESI’s innovative programs focus on unintended treatment-related effects that can adversely impact health and quality of life during and following cancer treatment.
Via the Biden Cancer Initiative, HESI is proud to announce the following commitments:
- HESI THRIVE makes cancer patient quality of life an active research priority. We are proud to launch the 2019 THRIVE grant awards here. A total of $225,000 will be awarded (4-6 grants). Letters of Intent are due October 19, 2018 at http://www.hesithrive.org. Awards announced January 11, 2019. Special thanks to THRIVE’s 2019 funders and partners: National Patient Advocate Foundation, Amgen, and HESI.
- THRIVE’s seed grants catalyze translational research on when and how adverse effects occur and how to avoid or lessen them. In THRIVE’s first year, grantees progressed areas such as neuropathic pain associated with breast cancer therapy, adverse effects from immunotherapy, and cardiac dysfunction associated with chemotherapies used to treat childhood cancers.
- In October 2019, we will also launch a global, public-private collaborative effort to innovate approaches for supporting the safety of oncologic therapies. We anticipate an initial focus on translational models for immuno-oncology safety but may adopt additional projects. Findings will be made publicly available upon completion. To date, individuals from the following organizations have made initial commitments to the design and launch of this HESI program: The National Patient Advocate Foundation, Medstar Health in Washington, MD Anderson, USC Ellison Institute for Transformative Medicine, U.S. Food and Drug Administration, Abcam, Amgen, Bristol-Myers Squibb, Sanofi, Takeda, Taconic, and HESI.
The Biden Cancer Initiative is an independent nonprofit organization committed to developing and driving the implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes. https://bidencancer.org